|
2024-01-08 |
2024-01-05 |
PlS
Planned sale
|
CHIEF SCIENTIFIC OFFICER
Officer
|
52,673
+1.3%
226.91
US$3,479,264
|
52,673
+1.3%
|
226.91
|
US$3,479,264
|
|
|
2024-01-05 |
2024-01-05 |
PrS
Proposed sale
|
Officer
Officer
|
43,599
488.02
US$1,783,186
|
43,599
|
488.02
|
US$1,783,186
|
|
|
2023-12-22 |
2023-12-21 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
35,595
+20.6%
453.18
US$373,175
|
35,595
+20.6%
|
453.18
|
US$373,175
|
|
|
2023-12-21 |
2023-12-21 |
PrS
Proposed sale
|
Officer
Officer
|
2,500
21.68
US$54,200
|
2,500
|
21.68
|
US$54,200
|
|
|
2023-11-29 |
2023-11-28 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
1,500
-7.9%
13.72
US$20,580
|
1,500
-7.9%
|
13.72
|
US$20,580
|
|
|
2023-11-28 |
2023-11-28 |
PrS
Proposed sale
|
Officer
Officer
|
1,500
13.72
US$20,580
|
1,500
|
13.72
|
US$20,580
|
|
|
2023-10-04 |
2023-10-03 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
2,500
-11.7%
15.77
US$39,425
|
2,500
-11.7%
|
15.77
|
US$39,425
|
|
|
2023-10-03 |
2023-10-03 |
PrS
Proposed sale
|
Officer
Officer
|
2,500
15.77
US$39,425
|
2,500
|
15.77
|
US$39,425
|
|
|
2023-08-22 |
2023-08-18 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
2,500
-10.5%
18.92
US$47,300
|
2,500
-10.5%
|
18.92
|
US$47,300
|
|
|
2023-08-18 |
2023-08-18 |
PrS
Proposed sale
|
Officer
Officer
|
2,500
18.92
US$47,300
|
2,500
|
18.92
|
US$47,300
|
|
|
2023-04-20 |
2023-04-19 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-19.2%
18.88
US$94,400
|
5,000
-19.2%
|
18.88
|
US$94,400
|
|
|
2023-04-19 |
2023-04-19 |
PrS
Proposed sale
|
Officer
Officer
|
5,000
18.88
US$94,400
|
5,000
|
18.88
|
US$94,400
|
|
|
2023-03-15 |
2023-03-14 |
B
Purchase
|
Non-Executive Director
|
2,500
+62.5%
20.05
US$50,125
|
2,500
+62.5%
|
20.05
|
US$50,125
|
|
|
2023-03-15 |
2023-03-14 |
B
Purchase
|
Non-Executive Director
|
600
+4.2%
19.95
US$11,970
|
600
+4.2%
|
19.95
|
US$11,970
|
|
|
2023-03-15 |
2023-03-14 |
B
Purchase
|
Non-Executive Director
|
400
+2.9%
18.48
US$7,392
|
400
+2.9%
|
18.48
|
US$7,392
|
|
|
2023-03-15 |
2023-03-14 |
B
Purchase
|
Non-Executive Director
|
1,500
+12.1%
18.75
US$28,125
|
1,500
+12.1%
|
18.75
|
US$28,125
|
|
|
2023-03-13 |
2023-03-07 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-16.4%
29.62
US$148,100
|
5,000
-16.4%
|
29.62
|
US$148,100
|
|
|
2023-01-26 |
2023-01-24 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-14.3%
30.00
US$150,000
|
5,000
-14.3%
|
30.00
|
US$150,000
|
|
|
2023-01-20 |
2023-01-19 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-12.5%
25.56
US$127,800
|
5,000
-12.5%
|
25.56
|
US$127,800
|
|
|
2023-01-09 |
2023-01-05 |
S
Sale
|
Chief Scientific Officer
Officer
|
742
-3.7%
21.97
US$16,299
|
742
-3.7%
|
21.97
|
US$16,299
|
|
|
2022-12-30 |
2022-12-29 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-11.7%
18.03
US$90,150
|
5,000
-11.7%
|
18.03
|
US$90,150
|
|
|
2022-11-29 |
2022-11-28 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-10.5%
17.87
US$89,350
|
5,000
-10.5%
|
17.87
|
US$89,350
|
|
|
2022-11-03 |
2022-11-02 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
5,000
-9.5%
22.32
US$111,600
|
5,000
-9.5%
|
22.32
|
US$111,600
|
|
|
2022-10-14 |
2022-10-13 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
2,000
-3.7%
21.52
US$43,040
|
2,000
-3.7%
|
21.52
|
US$43,040
|
|
|
2022-08-31 |
2022-08-30 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
2,500
-4.5%
28.13
US$70,325
|
2,500
-4.5%
|
28.13
|
US$70,325
|
|
|
2022-07-13 |
2022-07-11 |
S
Sale
|
Chief Medical Officer
Officer
|
2,000
-3.7%
19.95
US$39,900
|
2,000
-3.7%
|
19.95
|
US$39,900
|
|
|
2022-05-27 |
2022-05-25 |
B
Purchase
|
Large shareholder
|
63
+0.1%
12.45
US$785
|
63
+0.1%
|
12.45
|
US$785
|
|
|
2022-05-27 |
2022-05-25 |
B
Purchase
|
Large shareholder
|
1,837
+0.1%
12.45
US$22,880
|
1,837
+0.1%
|
12.45
|
US$22,880
|
|
|
2022-05-27 |
2022-05-25 |
B
Purchase
|
Large shareholder
|
63
+0.1%
12.45
US$785
|
63
+0.1%
|
12.45
|
US$785
|
|
|
2022-05-27 |
2022-05-25 |
B
Purchase
|
Large shareholder
|
1,837
+0.1%
12.45
US$22,880
|
1,837
+0.1%
|
12.45
|
US$22,880
|
|
|
2022-05-25 |
2022-05-24 |
B
Purchase
|
Large shareholder
|
538
+1.3%
12.00
US$6,457
|
538
+1.3%
|
12.00
|
US$6,457
|
|
|
2022-05-25 |
2022-05-24 |
B
Purchase
|
Large shareholder
|
15,776
+1.3%
12.00
US$189,345
|
15,776
+1.3%
|
12.00
|
US$189,345
|
|
|
2022-05-25 |
2022-05-24 |
B
Purchase
|
Large shareholder
|
538
+1.3%
12.00
US$6,457
|
538
+1.3%
|
12.00
|
US$6,457
|
|
|
2022-05-25 |
2022-05-24 |
B
Purchase
|
Large shareholder
|
15,776
+1.3%
12.00
US$189,345
|
15,776
+1.3%
|
12.00
|
US$189,345
|
|
|
2022-05-25 |
2022-05-23 |
B
Purchase
|
Large shareholder
|
338
+0.8%
12.50
US$4,225
|
338
+0.8%
|
12.50
|
US$4,225
|
|
|
2022-05-25 |
2022-05-23 |
B
Purchase
|
Large shareholder
|
9,898
+0.8%
12.50
US$123,718
|
9,898
+0.8%
|
12.50
|
US$123,718
|
|
|
2022-05-25 |
2022-05-23 |
B
Purchase
|
Large shareholder
|
338
+0.8%
12.50
US$4,225
|
338
+0.8%
|
12.50
|
US$4,225
|
|
|
2022-05-25 |
2022-05-23 |
B
Purchase
|
Large shareholder
|
9,898
+0.8%
12.50
US$123,718
|
9,898
+0.8%
|
12.50
|
US$123,718
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Large shareholder
|
41,250
+inf%
10.67
US$440,199
|
41,250
+inf%
|
10.67
|
US$440,199
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Large shareholder
|
1,208,750
+inf%
10.67
US$12,899,176
|
1,208,750
+inf%
|
10.67
|
US$12,899,176
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Non-Executive Director
|
400
+11.1%
10.62
US$4,248
|
400
+11.1%
|
10.62
|
US$4,248
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Non-Executive Director
|
600
+20.0%
10.49
US$6,294
|
600
+20.0%
|
10.49
|
US$6,294
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Non-Executive Director
|
1,000
+50.0%
10.51
US$10,510
|
1,000
+50.0%
|
10.51
|
US$10,510
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Non-Executive Director
|
500
+38.5%
11.30
US$5,650
|
500
+38.5%
|
11.30
|
US$5,650
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Non-Executive Director
|
2,500
+22.1%
11.80
US$29,500
|
2,500
+22.1%
|
11.80
|
US$29,500
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Non-Executive Director
|
2,000
+21.5%
10.54
US$21,080
|
2,000
+21.5%
|
10.54
|
US$21,080
|
|
|
2022-05-12 |
2022-05-10 |
PP
Planned purchase
|
Chief Financial Officer
Officer
|
5,000
+98.3%
10.53
US$52,650
|
5,000
+98.3%
|
10.53
|
US$52,650
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Large shareholder
|
41,250
+inf%
10.67
US$440,199
|
41,250
+inf%
|
10.67
|
US$440,199
|
|
|
2022-05-12 |
2022-05-10 |
B
Purchase
|
Large shareholder
|
1,208,750
+inf%
10.67
US$12,899,176
|
1,208,750
+inf%
|
10.67
|
US$12,899,176
|
|
|
2022-05-05 |
2022-05-04 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
720
-3.5%
15.05
US$10,836
|
720
-3.5%
|
15.05
|
US$10,836
|
|
|
2022-04-12 |
2022-04-11 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,647
-11.8%
23.05
US$61,013
|
2,647
-11.8%
|
23.05
|
US$61,013
|
|
|
2022-04-07 |
2022-04-06 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
3,000
-5.3%
22.96
US$68,880
|
3,000
-5.3%
|
22.96
|
US$68,880
|
|
|
2022-03-14 |
2022-03-11 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,648
-11.8%
23.91
US$63,314
|
2,648
-11.8%
|
23.91
|
US$63,314
|
|
|
2022-02-28 |
2022-02-28 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
3,000
-5.1%
18.79
US$56,370
|
3,000
-5.1%
|
18.79
|
US$56,370
|
|
|
2022-02-14 |
2022-02-11 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,647
-11.8%
22.47
US$59,478
|
2,647
-11.8%
|
22.47
|
US$59,478
|
|
|
2022-01-14 |
2022-01-13 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
3,000
-4.9%
30.67
US$92,010
|
3,000
-4.9%
|
30.67
|
US$92,010
|
|
|
2022-01-13 |
2022-01-11 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,648
-11.8%
32.16
US$85,160
|
2,648
-11.8%
|
32.16
|
US$85,160
|
|
|
2022-01-06 |
2022-01-05 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
2,000
-3.2%
40.00
US$80,000
|
2,000
-3.2%
|
40.00
|
US$80,000
|
|
|
2021-12-13 |
2021-12-10 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,647
-11.8%
30.88
US$81,739
|
2,647
-11.8%
|
30.88
|
US$81,739
|
|
|
2021-12-06 |
2021-12-03 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
3,000
-5.0%
32.26
US$96,780
|
3,000
-5.0%
|
32.26
|
US$96,780
|
|
|
2021-12-10 |
2021-11-11 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,648
-11.8%
35.69
US$94,507
|
2,648
-11.8%
|
35.69
|
US$94,507
|
|
|
2021-10-19 |
2021-10-18 |
B
Purchase
|
Non-Executive Director
|
500
+5.7%
30.70
US$15,350
|
500
+5.7%
|
30.70
|
US$15,350
|
|
|
2021-10-15 |
2021-10-13 |
B
Purchase
|
Non-Executive Director
|
400
+4.8%
29.69
US$11,876
|
400
+4.8%
|
29.69
|
US$11,876
|
|
|
2021-10-14 |
2021-10-13 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
3,000
-4.8%
29.69
US$89,070
|
3,000
-4.8%
|
29.69
|
US$89,070
|
|
|
2021-10-12 |
2021-10-11 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,647
-11.8%
30.78
US$81,475
|
2,647
-11.8%
|
30.78
|
US$81,475
|
|
|
2021-09-29 |
2021-09-27 |
S
Sale
|
Large shareholder
|
625
-100.0%
34.94
US$21,840
|
625
-100.0%
|
34.94
|
US$21,840
|
|
|
2021-09-29 |
2021-09-27 |
S
Sale
|
Large shareholder
|
1,114
-100.0%
34.97
US$38,951
|
1,114
-100.0%
|
34.97
|
US$38,951
|
|
|
2021-09-29 |
2021-09-27 |
S
Sale
|
Large shareholder
|
7,500
-100.0%
34.48
US$258,606
|
7,500
-100.0%
|
34.48
|
US$258,606
|
|
|
2021-09-14 |
2021-09-13 |
S
Sale
|
Large shareholder
|
4,788
-11.6%
35.28
US$168,942
|
4,788
-11.6%
|
35.28
|
US$168,942
|
|
|
2021-09-14 |
2021-09-13 |
S
Sale
|
Large shareholder
|
4,726
-6.1%
35.27
US$166,692
|
4,726
-6.1%
|
35.27
|
US$166,692
|
|
|
2021-09-14 |
2021-09-13 |
S
Sale
|
Large shareholder
|
4,803
-6.2%
35.25
US$169,309
|
4,803
-6.2%
|
35.25
|
US$169,309
|
|
|
2021-09-14 |
2021-09-10 |
S
Sale
|
Large shareholder
|
7,231
-14.9%
35.19
US$254,494
|
7,231
-14.9%
|
35.19
|
US$254,494
|
|
|
2021-09-14 |
2021-09-10 |
S
Sale
|
Large shareholder
|
7,320
-8.7%
35.19
US$257,572
|
7,320
-8.7%
|
35.19
|
US$257,572
|
|
|
2021-09-14 |
2021-09-10 |
S
Sale
|
Large shareholder
|
7,187
-8.5%
35.19
US$252,940
|
7,187
-8.5%
|
35.19
|
US$252,940
|
|
|
2021-09-13 |
2021-09-10 |
PlS
Planned sale
|
Chief Scientific Officer
Officer
|
2,648
-11.8%
35.78
US$94,745
|
2,648
-11.8%
|
35.78
|
US$94,745
|
|